[BriaCell Therapeutics Corp.] BriaCell Therapeutics Corp., announced that its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.
[Ion Beam Applications S.A.] Ion Beam Applications S.A. (IBA), and the University Medical Center Groningen (UMCG) announced a four-year research collaboration agreement towards development of a new FLASH irradiation protocol for the treatment of early-stage breast cancer.
[Matrix Biology] Scientists reported that estrogen receptor (ER)-positive breast cancers had lower hyaluronan synthase 2 antisense RNA 1 (HAS2-AS1) expression compared to ER-negative tumors. Moreover, the survival of patients with ER-negative tumors was higher when the expression of HAS2-AS1 was elevated.
[Cell Reports] The authors showed that high feline sarcoma-related non-receptor tyrosine kinase (FER) levels were also associated with improved outcomes after adjuvant taxane-based combination chemotherapy in high-risk, HER2-negative patients.
[Cell Death & Disease] Investigators showed that when Hsp70-binding protein 1 (HspBP1) was either knocked down or overexpressed in BRCA1-proficient breast cancer cells, there were profound changes in tumorigenesis, including anchorage-independent cell growth in vitro and in tumor formation in xenograft models.